2003054467

19 AUG 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037258 A1

(51) International Patent Classification[7]: A61K 31/4745, A61P 35/00, A61K 31/47, 31/4745, 31/138

(21) International Application Number: PCT/EP2002/006758

(22) International Filing Date: 15 March 2002 (15.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/275,627 15 March 2001 (15.03.2001) US

(71) Applicant: AVENTIS PHARMA S.A. [FR/FR]; 20, avenue Raymond Aron, F-92160 Antony (FR).

(72) Inventor: BISSERY, Marie-Christine; 5, rue Henri-Poincaré, F-94400 Vitry-sur-Seine (FR).

(74) Agent: LE PENNEC, Magali; Aventis Pharma S.A., Patent Department - K2/144, 20, avenue Raymond Aron, F-92165 Antony Cedex (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

ACTION

WO 2004/037258 A1

(54) Title: A COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS

(57) Abstract: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, epidophylloptoxins, and antibiotics as the active ingredients is provided. There are also provided methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like.